🇺🇸 FDA
Patent

US 10238735

Controlled activation of complement components for use as endogenous adjuvant

granted A61KA61K2039/55516A61K39/292

Quick answer

US patent 10238735 (Controlled activation of complement components for use as endogenous adjuvant) held by PLS-Design GmbH expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PLS-Design GmbH
Grant date
Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/55516, A61K39/292, A61K39/39, A61K9/0024